Brought to you by 
Denali, Lonza collaborate on biologics for neurodegenerative diseases
06 Mar 2018
Executive Summary
Denali Therapeutics Inc. is collaborating with Lonza Group Ltd. to advance Denali’s biologic pipeline of neurodegenerative disease compounds through all stages of development and manufacturing.
Deal Industry
- Pharmaceuticals
- Services
-
Biotechnology
- Large Molecule
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Denali, Lonza collaborate on biologics for neurodegenerative diseases
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice